-$0.41 EPS Expected for Protagonist Therapeutics Inc (PTGX) This Quarter
Equities analysts forecast that Protagonist Therapeutics Inc (NASDAQ:PTGX) will post earnings of ($0.41) per share for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Protagonist Therapeutics’ earnings. The highest EPS estimate is ($0.12) and the lowest is ($0.69). Protagonist Therapeutics reported earnings of ($0.29) per share during the same quarter last year, which would suggest a negative year over year growth rate of 41.4%. The firm is expected to issue its next earnings report on Monday, November 5th.
On average, analysts expect that Protagonist Therapeutics will report full-year earnings of ($1.01) per share for the current financial year, with EPS estimates ranging from ($1.28) to ($0.73). For the next fiscal year, analysts forecast that the business will report earnings of ($1.75) per share, with EPS estimates ranging from ($2.20) to ($1.29). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Protagonist Therapeutics.
Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings data on Tuesday, August 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.07). Protagonist Therapeutics had a negative return on equity of 24.16% and a negative net margin of 56.92%. The firm had revenue of $11.67 million during the quarter, compared to the consensus estimate of $8.55 million.
NASDAQ:PTGX opened at $8.88 on Thursday. The company has a market capitalization of $213.64 million, a price-to-earnings ratio of -4.25 and a beta of 3.75. Protagonist Therapeutics has a 1 year low of $5.50 and a 1 year high of $23.97.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. American Century Companies Inc. bought a new stake in Protagonist Therapeutics during the 1st quarter valued at $1,227,000. Prudential Financial Inc. bought a new stake in Protagonist Therapeutics during the 1st quarter valued at $116,000. Schwab Charles Investment Management Inc. raised its position in Protagonist Therapeutics by 67.4% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 32,315 shares of the company’s stock valued at $278,000 after purchasing an additional 13,015 shares in the last quarter. BlackRock Inc. raised its position in Protagonist Therapeutics by 39.0% during the 1st quarter. BlackRock Inc. now owns 687,160 shares of the company’s stock valued at $5,904,000 after purchasing an additional 192,632 shares in the last quarter. Finally, Federated Investors Inc. PA raised its position in Protagonist Therapeutics by 266.8% during the 1st quarter. Federated Investors Inc. PA now owns 63,921 shares of the company’s stock valued at $549,000 after purchasing an additional 46,496 shares in the last quarter. Institutional investors own 57.93% of the company’s stock.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based drugs to address various unmet medical needs. The company's lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin- antagonist that is in Phase II b clinical trial for the treatment of ulcerative colitis, as well as for treating chronic pouchitis, a gastrointestinal (GI) condition that occurs in post-surgical inflammatory bowel disease (IBD) patients; PTG-200, an oral interleukin-23 receptor antagonist, which is in Phase I clinical trial for the treatment of IBD; and PTG-300, an injectable hepcidin mimetic, which has completed Phase I study for use in the treatment of beta-thalassemia, as well as for treating other diseases, such as hereditary hemochromatosis, polycythemia vera, siderophilic infections, and liver fibrosis.
Recommended Story: Marijuana Stocks Investing Considerations
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.